SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Pandion Therapeutics, Inc. Buyout

Rigrodsky Law, P.A. announces that it is investigating Pandion Therapeutics, Inc. ("Pandion") (NASDAQ GS: PAND ) regarding possible breaches of fiduciary duties and other violations of law related to Forterra's agreement to be acquired by Merck & Co., Inc. ("Merck") (NYSE: MRK ). Under the terms of the agreement, Pandion's shareholders will receive $60.00 in cash per share.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-pandion-inc .

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com .

Rigrodsky Law, P.A. , with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

CONTACT:

Rigrodsky Law, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
https://rl-legal.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

pharmaceutical investing
The Conversation (0)
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+

Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturingProgram builds on BriaCell's experience in metastatic... Keep Reading...
Stacks of white pills progressively increase in height from left to right on a solid blue background.

Moderna, Merck Shares Soar on Cancer Vaccine Trial Success

An experimental personalized mRNA vaccine developed by Moderna (NASDAQ:MRNA) and Merck & Company (NYSE:MRK) successfully prevented skin cancer from returning in a late-stage clinical trial, sending shares of both drugmakers surging on Wednesday (August 19).The Phase 3 study evaluated the... Keep Reading...
Various colorful pills and tablets spill from an orange prescription bottle onto a blue background.

Eli Lilly Surges, Novo Nordisk Slips in Weight-Loss War

Eli Lilly and Company (NYSE:LLY) and Novo Nordisk (NYSE:NVO) both raised their full-year profit outlooks on the back of explosive demand for GLP-1 weight-loss and diabetes treatments. But by mid-year, Eli Lilly's blockbuster injectable drugs propelled its valuation past US$1 trillion, while Novo... Keep Reading...
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components... Keep Reading...
US Food and Drug Administration website on a phone screen.

Eli Lilly Cancer Drug Wins FDA Breakthrough Therapy Status

The US Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Eli Lilly and Company's (NYSE:LLY) experimental drug olomorasib as a standalone treatment for patients with advanced pancreatic cancer and a KRAS G12C mutation who have received at least one systemic... Keep Reading...
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

5 Best-performing Canadian Pharma Stocks in 2026

From established players to up-and-coming firms, Canada's pharmaceutical landscape is diverse and dynamic.Canadian drug companies are working to discover, develop and commercialize major innovations amid an increasingly competitive global landscape. Rising technologies such as artificial... Keep Reading...

Latest News

More News

Interactive Chart

Latest Press Releases

QIMC Drills New Company Record of 27.8% Clean Natural Hydrogen at Just 374 Metres at Bennett Hill, Nova Scotia

Nine Mile Metals DDH WD-26-07 Intersects High Grade VMS Zones Including 24m of 2.77% Cu-Eq and 9.2m of 4.14% Cu-Eq

NevGold Expands Recent Mineral Resource Estimate With First 2026 Drillholes; 1.16% Antimony Over 3.0 Meters Within 1.38 g/t AuEq Over 50.3 Meters From Surface

SAGA Metals Completes Mineral Resource Estimate Drill Program at Radar Critical Minerals Project in Labrador

Related News

copper investing

EXIM Backs Ivanhoe Copper Mine With US$1.1 Billion Financing

gold investing

Agnico Eagle Takes US$41.1 Million Stake in Radisson Mining

QIMC Drills New Company Record of 27.8% Clean Natural Hydrogen at Just 374 Metres at Bennett Hill, Nova Scotia

copper investing

Nine Mile Metals DDH WD-26-07 Intersects High Grade VMS Zones Including 24m of 2.77% Cu-Eq and 9.2m of 4.14% Cu-Eq

precious metals investing

NevGold Expands Recent Mineral Resource Estimate With First 2026 Drillholes; 1.16% Antimony Over 3.0 Meters Within 1.38 g/t AuEq Over 50.3 Meters From Surface

battery metals investing

SAGA Metals Completes Mineral Resource Estimate Drill Program at Radar Critical Minerals Project in Labrador

precious metals investing

Graycliff Shakespeare Drilling Update